The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2017Identification and Optimization of beta-Glucocerebrosidase Modulators for Parkinson's Disease
Study Rationale:
Genetic studies have demonstrated that the GBA1 gene encoding beta-glucocerebrosidase (GCase) (an enzyme that breaks down fats) is a major risk factor for Parkinson's disease (PD)... -
Improved Biomarkers and Clinical Outcome Measures, 2017Neuron-restricted RNA Profiles in the Plasma of Those with Genetic and Sporadic Parkinson's Disease
Study Rationale:
MicroRNAs (miRs) are short RNA molecules (messengers that carry genetic information to DNA) that block protein expression by crossing with hundreds of mRNA targets. Neuron-restricted... -
Research Grant, 2017Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease
Study Rationale:
Previous research has shown higher levels of the c-Abl protein are activated in the brains of people with Parkinson's disease (PD), and studies have linked c-Abl to pathways associated... -
Target Advancement Program, 2017A Novel Role for Galectin Proteins in the Neuronal Response to Alpha-synuclein Invasion
Study Rationale:
Galectins proteins (proteins that bind sugar molecules) mediate the cellular response to endocytic (transfer of molecules to cells) vesicles (storage sacks) ruptured by amyloid... -
Research Grant, 2017Standard Operating Procedures for Alpha-synuclein Analysis in Biological Fluids Using a Colorimetric Immunoassay (SYN-SOP)
Study Rationale:
The alpha-synuclein protein accumulates in structures called Lewy bodies in the brains of those with Parkinson's disease (PD). These protein clumps are considered to be one of the key... -
Target Advancement Program, 2017Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release
Study Rationale:
Synucleinopathies, including Parkinson's disease (PD), are a family of central nervous system (CNS) degenerative disorders characterized by alpha-synuclein protein-containing...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.